1mg

Prostate specific antigen (PSA) is a serine protease produced by the prostate gland. In serum, it exists in different forms, cPSA, mainly including PSA-ACT (alpha-1-antichymotrypsin) and PSA-A2M (alpha-2-macroglobulin), fPSA (free PSA), etc. The blood level of PSA is increased in men with prostate cancer and it is considered as an indicator for prostate cancer, tumor recurrence and response to therapy.

Prostate specific antigen (PSA) is a serine protease produced by the prostate gland. In serum, it exists in different forms, cPSA, mainly including PSA-ACT (alpha-1-antichymotrypsin) and PSA-A2M (alpha-2-macroglobulin), fPSA (free PSA), etc. The blood level of PSA is increased in men with prostate cancer and it is considered as an indicator for prostate cancer, tumor recurrence and response to therapy.

PSA monoclonal antibodies (5B10D4, 8A9B8, 1G9G8, 4A5D10 and 1A7D4) recognize total PSA, freePSA and ACT- PSA Complex (Prostate Specific Antigen / a-1 Antichymotrypsin Complex).

Prostate-specific membrane antigen (PSMA) also known as Folate hydrolase 1 (FOLH1), Folylpoly-gamma-glutamate carboxypeptidase (FGCP), Glutamate carboxypeptidase 2 (GCP2), N-acetylated-alpha-linked acidic dipeptidase I (NAALAD1), is a type II membrane glycoprotein that is expressed in prostate tissue and to a lesser extent in the peripheral and central nervous system, small intestinal, and salivary gland tissues. PSMA has both folate hydrolase and N-acetylated-alpha-linked-acidic dipeptidase (NAALADase) activity and has a preference for tri-alpha-glutamate peptides. The catalytic activity of PSMA involves the release of unsubstituted C-terminal glutamyl residues, typically from Ac-Asp-Glu or folylpoly-gamma-glutamates. PSMA is used as a diagnostic and prognostic indicator of prostate cancer, and as a possible marker for various neurological disorders such as schizophrenia, Alzheimer’s disease, and Huntington’s disease.

Prostate-specific membrane antigen (PSMA) also known as Folate hydrolase 1 (FOLH1), Folylpoly-gamma-glutamate carboxypeptidase (FGCP), Glutamate carboxypeptidase 2 (GCP2), N-acetylated-alpha-linked acidic dipeptidase I (NAALAD1), is a type II membrane glycoprotein that is expressed in prostate tissue and to a lesser extent in the peripheral and central nervous system, small intestinal, and salivary gland tissues. PSMA has both folate hydrolase and N-acetylated-alpha-linked-acidic dipeptidase (NAALADase) activity and has a preference for tri-alpha-glutamate peptides. The catalytic activity of PSMA involves the release of unsubstituted C-terminal glutamyl residues, typically from Ac-Asp-Glu or folylpoly-gamma-glutamates. PSMA is used as a diagnostic and prognostic indicator of prostate cancer, and as a possible marker for various neurological disorders such as schizophrenia, Alzheimer’s disease, and Huntington’s disease.

Parathyroid Hormone (PTH) is the most important endocrine regulator of calcium and phosphorus con- centration in extracellular fluid. Parathyroid Hormone (PTH) is secreted from cells of the parathyroid glands and finds Parathyroid Hormone’s major target cells in bone and kidney. Like most other protein hormones, Parathyroid Hormone (PTH) is synthesized as a preprohormone. After intracellular processing, the mature hormone is packaged within the Golgi into secretory vesicles, the secreted into blood by exocytosis. Parathyroid Hormone (PTH) is secreted as a linear protein of 84 amino acids. Recombinant Human Parathyroid Hormone (PTH) produced in E. coli is a single, non-glycosylated, polypeptide chain containing 84 amino acids.

Polypeptide hormones secreted by the parathyroid glands, which promote release of calcium from bone to extracellular fluid by activating osteoblasts and inhibiting osteoclasts, indirectly promote increased intestinal absorption of calcium, and promote renal tubular reabsorption of calcium and increased renal excretion of phosphates. It is a major regulator of bone metabolism. Secretion of parathyroid hormone increases when the level of calcium in the extracellular fluid is low. Its action is opposed by calcitonin.

beta test product of PTH Antibody (8H4HC)

beta test product of PTH Antibody (NT7HC)

Parathyroid
hormone (PTH) is synthesized by the parathyroid glands and secreted into the
blood stream. Intact PTH is a single polypeptide containing 84 amino acids.
PTH, which plays an important role in maintaining calcium homeostasis, is a
useful biomarker in the diagnosis of calcium related disorders.

Parathyroid
hormone (PTH) is synthesized by the parathyroid glands and secreted into the
blood stream. Intact PTH is a single polypeptide containing 84 amino acids.
PTH, which plays an important role in maintaining calcium homeostasis, is a
useful biomarker in the diagnosis of calcium related disorders.

PVR is a Type I transmembrane glycoprotein in the immunoglobulin superfamily. Commonly known as Poliovirus Receptor (PVR) due to its involvement in the cellular poliovirus infection in primates. PVR’s normal cellular function is in the establishment of intercellular adherens junctions between epithelial cells. PVR/CD155 was originally isolated based on its ability to mediate polio virus attachment to host cells. The full length (or PVR alpha isoform) is synthesized as a 417 amino acid (aa) precursor that contains a 20aa signal sequence, a 323aa extracellular region, a 24aa TM segment and a 50aa cytoplasmic tail. PVR binds other molecules including Vitronectin, Nectin-3, DNAM-1/CD226, CD96, and TIGIT but does not bind homotypically. PVR is up-regulated on endothelial cells by IFN-gamma and is highly expressed on immature thymocytes, lymph node dendritic cells, and tumor cells of epithelial and neuronal origin.

CCL5 or RANTES (acronym for Regulated upon Activation, Normal T cell Expressed and presumably Secreted), was initially discovered by subtractive hybridization as a transcript expressed in T cells but not B cells. Eosinophilchemotactic activities released by thrombinstimulated human platelets have also been purified and found to be identical to RANTES. Besides T cells and platelets, RANTES has been reported to be produced by renal tubular epithelium, synovial fibroblasts and selected tumor cells.

The properties of retinol binding protein is the transport carrier of vitamin A in the plasma. Human-retinol binding protein is a single-chain polypeptide with a molecular weight of approximately 21000 and one binding site for retinol and other forms of vitamin A. In addition, compounds related to retinol, such as retinal, retinoic acid, retinyl esters and geometric isomers of retinol and of retinal were evaluated for their ability to bind to this protein. In plasma, RBP4-retinol forms a complex with transthyretin (TTR), also known as thyroxine-binding protein and prealbumin. Defects in RBP4 cause retinol-binding protein deficiency, which affects night vision.

Protein Induced by Vitamin K Absence or Antagonist-II (PIVKA-II), also known as Des-γ-carboxy-prothrombin (DCP), is an abnormal form of prothrombin. Normally, the prothrombin’s 10 glutamic acid residues (Glu) in the γ-carboxyglutamic acid (Gla) domain at positions 6, 7, 14, 16, 19, 20,25, 26, 29 and 32 are γ-carboxylated to Gla by vitamin-K dependent γ- glutamyl carboxylase in the liver and then secreted into plasma. In patients with hepatocellular carcinoma (HCC), γ-carboxylation of prothrombin is impaired so that PIVKA-II is formed instead of prothrombin. PIVKA-II is considered as is an efficient biomarker specific for HCC.

ROR1 (Receptor tyrosine kinase-like orphan receptor 1), also known as neurotrophic tyrosine kinase receptor-related 1 (NTRKR1), is a member of the ROR family within the receptor tyrosine kinases (RTK) superfamily. Two ROR family members (ROR1 and ROR2) have been identified and are characterized by the intracellular tyrosine kinase domains, highly related to those of the Trk-family receptor tyrosine kinases, and by the extracellular Frizzled-like cysteine-rich domains and kringle domains, which are common to receptors of the Wnt family members.

RSPO1 is a secreted protein, containing 2 FU(furin-like) repeats and 1 TSP type-1 domain and belonging to the R-spondin family. RSPO1 is required for the early development of gonads, regardless of sex. It has been found in mice only eleven days after fertilization. To induce cell proliferation, it acts synergistically with WNT4. They help stabilize β catenin, which activates downstream targets. RSPO1 is necessary in female sex development. It augments the WNT/β catenin pathway to oppose male sex development. In critical gonadal stages, between six and nine weeks after fertilization, the ovaries upregulate it while the testes downregulate it. RSPO1 can potentially aid in the treatment of mucositis, which is characterized by inflammation of the oral cavity. This unfortunate condition often accompanies chemotherapy and radiation in cancer patients with head and neck tumors.

S100 protein family contains variety of members such as ββ homodimer and αβ heterodimer. It is a useful marker for monitoring brain damage and detecting secondary neurological injuries. The concentration of S100 A8/A9 hetero complex increases in blood when special diseases take places, such as rheumatoid arthritis, cystic fibrosis, multiple scerlosis, and HIV infections. S100A8/A9 protein is a potential serum marker for diagnosis of pancreatic ductal adenocarcinoma (PDAC), intraductal papillary mucinous neoplasm (IPMN) or chronic pancreatitis (CP).

S100 protein family contains variety of members such as ββ homodimer and αβ heterodimer. It is a useful marker for monitoring brain damage and detecting secondary neurological injuries. The concentration of S100 A8/A9 hetero complex increases in blood when special diseases take places, such as rheumatoid arthritis, cystic fibrosis, multiple scerlosis, and HIV infections. S100A8/A9 protein is a potential serum marker for diagnosis of pancreatic ductal adenocarcinoma (PDAC), intraductal papillary mucinous neoplasm (IPMN) or chronic pancreatitis (CP)

S100 protein family contains variety of members such as ββ homodimer and αβ heterodimer. It is a useful marker for monitoring brain damage and detecting secondary neurological injuries. The concentration of S100 A8/A9 hetero complex increases in blood when special diseases take places, such as rheumatoid arthritis, cystic fibrosis, multiple scerlosis, and HIV infections. S100A8/A9 protein is a potential serum marker for diagnosis of pancreatic ductal adenocarcinoma (PDAC), intraductal papillary mucinous neoplasm (IPMN) or chronic pancreatitis (CP).

Serum Amyloid A (SAA) is an acute-phase protein. The concentration of SAA in blood increases rapidly when tissue damage or inflammation occurs. It is considered as an early biomarker for the diagnosis of many inflammatory diseases. SAA can also be used as an important indicator of infection.

Serum Amyloid A (SAA) is an acute-phase protein. The concentration of SAA in blood increases rapidly when tissue damage or inflammation occurs. It is considered as an early biomarker for the diagnosis of many inflammatory diseases. SAA can also be used as an important indicator of infection.

Serum Amyloid A (SAA) is an acute-phase protein. The concentration of SAA in blood increases rapidly when tissue damage or inflammation occurs. It is considered as an early biomarker for the diagnosis of many inflammatory diseases. SAA can also be used as an important indicator of infection.

Serum Amyloid A (SAA) is an acute-phase protein. The concentration of SAA in blood increases rapidly when tissue damage or inflammation occurs. It is considered as an early biomarker for the diagnosis of many inflammatory diseases. SAA can also be used as an important indicator of infection.

Serum Amyloid A (SAA) is an acute-phase protein. The concentration of SAA in blood increases rapidly when tissue damage or inflammation occurs. It is considered as an early biomarker for the diagnosis of many inflammatory diseases. SAA can also be used as an important indicator of infection.

GenScript SARS-CoV-2 ADE-Causing Antibody (S9HC) reacts with SARS-CoV-2 Spike protein of wild type and delta variant. It can obviously enhance the SARS-COV-2 binding with ACE2.

The product is specific for SARS-CoV-2 Spike Protein S1 subunit and its RBD domain

The product is specific for SARS-CoV-2 Spike Protein S1 subunit and its RBD domain

The product is specific for SARS-CoV-2 Spike Protein S1 subunit and its RBD domain

The product is specific for SARS-CoV-2 Spike Protein S1 subunit and its RBD domain. The product can recognize and neutralize Wild-Type SARS-CoV-2 and Variants of Concern (VOC) including Alpha, Beta, Delta, and Omicron. Reactivity with Gamma variant has not been tested.

The product is specific for SARS-CoV-2 Nucleocapsid protein.

The product is specific for SARS-CoV-2 Nucleocapsid protein.

The product is specific for SARS-CoV-2 Nucleocapsid protein.

The product is specific for SARS-CoV-2 Nucleocapsid protein.

The product is specific for SARS-CoV-2 Nucleocapsid protein.

The product is specific for SARS-CoV-2 Nucleocapsid protein.

SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) also known as 2019-nCoV (2019 Novel Coronavirus) is a virus that causes illnesses ranging from the common cold to severe diseases. SARS-CoV-2 Nucleocapsid Protein is associated with nucleic acid. It is the most abundant protein for coronavirus. Because of the strong immunogenicity of coronavirus Nucleocapsid, it is believed that SARS-CoV-2 Nucleocapsid Protein has potential value for the diagnosis of the virus.

SARS-CoV-2 (Severe acute respiratory syndrome coronavirus 2), also known as 2019-nCoV, is a positive-sense single-stranded RNA virus. It caused coronavirus disease 2019 (COVID-19). Nucleocapsid Protein is the most abundant structural protein of the coronavirus which is associated with the nucleic acid. The sublineage B.1.617.2 has been redesignated as a “variant of concern” (VOC-21APR-02) in May 2021, which spreads more quickly than the original version of the virus.

SARS-CoV-2 (Severe Acute Respiratory
Syndrome Coronavirus 2) also known as 2019-nCoV (2019 Novel Coronavirus) is a virus that causes illnesses ranging from the common cold to severe diseases. Recently, the new B.1.1.529 variant was confirmed in South Africa and preliminary evidence suggests an increased risk of reinfection with this variant. The B.1.1.529 variant was first reported to WHO on 24 November 2021 and WHO has designated this variant as a VOC (Variant of Concern), named Omicron. There are more than 30 mutations in the spike protein.

SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) also known as 2019-nCoV (2019 Novel Coronavirus) is a virus that causes illnesses ranging from the common cold to severe diseases. SARS-CoV-2 Nucleocapsid Protein is associated with nucleic acid. It is the most abundant protein for coronavirus. Because of the strong immunogenicity of coronavirus Nucleocapsid, it is believed that SARS-CoV-2 Nucleocapsid Protein has potential value for the diagnosis of the virus.

SARS-CoV-2 Spike (484Q) Antibody (Q8), mAb, Mouse is specific for 484Q site of B.1.617 SARS-CoV-2. This product can recognize single mutant (E484Q) and double mutant (L452R, E484Q), but can not recognize the wild type and single mutant (L452R).

The product is specific for E484 site of wild-type RBD.For specific mutant protein, the product recognizes wild-type RBD, RBD single mutant (N501Y), and RBD single mutant (K417N), but not recognizes RBD single mutant (E484K) and RBD triple mutant (K417N, E484K and N501Y), as seen in Figure 2.

The product is specific for N501 site of wild-type RBD.For specific mutant protein, the product recognizes wild-type RBD, RBD single mutant (E484K), and RBD single mutant (K417N), but not recognizes RBD single mutant (N501Y) and RBD triple mutant (K417N, E484K and N501Y), as seen in Figure 2.

SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) also known as 2019-nCoV (2019 Novel Coronavirus) is a virus that causes illnesses ranging from the common cold to severe diseases. SARS-CoV-2 Spike Protein is composed of S1 domain and S2 domain. S1 contains a receptor-binding domain (RBD) that can specifically bind to angiotensin-converting enzyme 2 (ACE2), the receptor on target cells. ECD is the extra cellular domain of spike protein.

SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) also known as 2019-nCoV (2019 Novel Coronavirus) is a virus that causes illnesses ranging from the common cold to severe diseases. SARS-CoV-2 Spike Protein is composed of S1 domain and S2 domain. S1 contains a receptor-binding domain (RBD) that can specifically bind to angiotensin-converting enzyme 2 (ACE2), the receptor on target cells. It is believed that SARS-CoV-2 Spike Protein (RBD) has potential value for the diagnosis of the virus.

SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) also known as 2019-nCoV (2019 Novel Coronavirus) is a virus that causes illnesses ranging from the common cold to severe diseases. Lineage P.1, also known as the Brazil(ian) variant is one of the variants of SARS-CoV-2. This variant has 17 amino acid changes, ten of which are in its spike protein, including these three designated to be of particular concern: N501Y, E484K and K417T. SARS-CoV-2 Spike protein (RBD, E484K, K417T, N501Y, Avi & His Tag) carries a Avi Tag followed by a polyhistidine tag at the C-terminus. It has high binding affinity to human chimeric ACE2.

SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) also known as 2019-nCoV (2019 Novel Coronavirus) is a virus that causes illnesses ranging from the common cold to severe diseases. SARS-CoV-2 Spike Protein is composed of S1 domain and S2 domain. S1 contains a receptor-binding domain (RBD) that can specifically bind to angiotensin-converting enzyme 2 (ACE2), the receptor on target cells. It is believed that SARS-CoV-2 Spike Protein (RBD) has potential value for the diagnosis of the virus.

SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) also known as 2019-nCoV (2019 Novel Coronavirus) is a virus that causes illnesses ranging from the common cold to severe diseases. SARS-CoV-2 Spike Protein is composed of S1 domain and S2 domain. S1 contains a receptor-binding domain (RBD) that can specifically bind to angiotensin-converting enzyme 2 (ACE2), the receptor on target cells. It is believed that SARS-CoV-2 Spike Protein (RBD) has potential value for the diagnosis of the virus.

SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) also known as 2019-nCoV (2019 Novel Coronavirus) is a virus that causes illnesses ranging from the common cold to severe diseases. As of May 2021, three sublineages have been found. Despite its name, B.1.617.3 was the first sublineage of this variant to be detected, in October 2020 in India. This sublineage has remained relatively uncommon compared to the two other sublineages, B.1.617.1 (also known as variant Kappa) and B.1.617.2 (also known as variant Delta), both of which were first detected in December 2020. This variant has the double mutations E484Q and L452R in the spike proteins. Emerging research suggests the variant may be more transmissible than previously evolved ones. Whether the effectiveness of currently-deployed vaccines is affected remains under investigation. Moreover, the sublineage B.1.617.2 has been redesignated as “variant of concern” (VOC-21APR-02) in May 2021, which spreads more quickly than the original version of the virus.

SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) also known as 2019-nCoV (2019 Novel Coronavirus) is a virus that causes illnesses ranging from the common cold to severe diseases. SARS-CoV-2 Spike Protein is composed of S1 domain and S2 domain. S1 contains a receptor-binding domain (RBD) that can specifically bind to angiotensin-converting enzyme 2 (ACE2), the receptor on target cells. It is believed that SARS-CoV-2 Spike Protein (RBD) has potential value for the diagnosis of the virus.